Clinical trial · Observational
Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Route and Adequacy of Nutrition and Outcomes of Haematopoietic Cell Transplantation in Patients With Haematological Neoplasms
NCT03419078CI-TRIAL-00041206completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Allogeneic Stem Cell Transplant | — | UNRESOLVED | — |
| Graft Versus Host Disease | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Stem Cell Transplant Complications | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Number of Participants With Acute Graft Versus Host Disease (GvHD) at Any Site (Grade II or Above) and Acute GvHD of the Gut of Any Grade
- timeFrame
- 100 days after the date of hematopoietic cell infusion
- description
- Occurrence of acute GvHD at any site (grade II or above) and acute GvHD of the gut of any grade (graded according to standard criteria). Standard criteria to grade the severity of acute GvHD are quantification of rash, serum bilirubin and diarrhoea. These standard criteria have been developed and used for \> 20 years by most transplant centres to improve comparability between publications.
- measure
- Non Relapse Mortality
- timeFrame
- 100 days after the date of hematopoietic cell infusion
- description
- Defined as death without previous relapse
Secondary outcomes (2)
- measure
- Graft Versus Host Disease-free and Relapse-free Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing their first HCT for a hematologic malignancy * Undergoing HCT using a sibling or unrelated donor * Undergoing HCT infusion between January 2000 and December 2014 Exclusion Criteria: * HCT using umbilical cord blood donors * HCT using haploidentical donors
References
Publications (0)
Data not yet available
No reference posted for this study.